August 11, 2008


In-ovo vaccination makes inroads into UK


Use of in ovo vaccination is likely to expand considerably in the UK and other European countries as new approved vaccines become available, according to Farmers' Weekly. 


The method is already delivering Marek's disease vaccine in-ovo to about 85 percent of US broilers.

In the UK, as free-range and organic poultry are gaining in popularity so has the need for in ovo vaccination.
In the UK egg sector, day-old chicks are routinely vaccinated against Marek's in the hatchery. But, as only females are required in production, this would mean double the cost of in ovo treatment. Still, this has not prevented in-ovo vaccination from being used by primary breeding companies in the UK, who value its precision and reliability.
In-ovo vaccination provides earlier exposure to vaccines, which can reduce disease resistance and promote early chick health, the paper said.


Traditional methods of vaccine delivery may result in human error while automatic systems, which punches a hole in the egg shell to deliver the vaccine, was considered more reliable.


An example of a system is the Embrex Inovoject System.


Worldwide, more than 600 systems are being used in over 30 countries. The largest use is in the US, where the technique delivers Marek's vaccine to about 150 million  broilers a week

Vaccine companies, recognising the potential in in-ovo vaccines, are rushing to roll out such products.
An introduction by Pfizer to the US later this year is Inovocox, a live oocyst containing vaccine for preventing coccidiosis, which could replace feed additives commonly used to control it.
Merial Animal Health also offers a combined Gumboro and Marek's disease vaccine launched initially in Brazil in 2006.
Video >

Follow Us